Skip to content

Study · Non-randomized trial · n = 12 · 2012

4 results

GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist.

Andreassen M, Frystyk J, Faber J, Kristensen LØ

European journal of endocrinology9 Mar 2012Cited by 25 (Europe PMC)

PMID22408123 (opens in a new tab)DOI10.1530/eje-11-1009 (opens in a new tab)PepBankPUB-22408123
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, pegvisomant reduced IGF1 from 139 (117-171) to 91 (78-114) ng/ml (P=0.005).

    In plain wordsIn healthy volunteers, pegvisomant reduced IGF1 compared with before treatment.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF1
    Study

    n = 12

    Comparator
    Before pegvisomant treatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/day first week, 15 mg/day last two weeks · 3 weeksAs given in this study (human).

    Measurements

    IGF1 median
    139 ng/ml
    before pegvisomant treatment
    IGF1 interquartile range
    117 to 171 ng/ml
    before pegvisomant treatment
    IGF1 median
    91 ng/ml
    during pegvisomant treatment
    IGF1 interquartile range
    78 to 114 ng/ml
    during pegvisomant treatment

    Source sentences

    Summary
    During pegvisomant treatment, IGF1 decreased (139 (117-171) vs 91 (78-114) ng/ml, P=0.005).
    2 context sentences
    Summary · context
    Twelve healthy volunteers (mean age 36, range 27-49 years) were treated in random order
    Summary · context
    or a GH receptor antagonist (pegvisomant; first week 10  mg/day and last two weeks 15  mg/day), separated by 8 weeks of washout.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, orosomucoid increased from 21.0 (16.3-23.8) to 22.0 (17.0-29.3) μM during pegvisomant treatment (P=0.036).

    In plain wordsIn healthy volunteers, orosomucoid increased during pegvisomant treatment compared with before treatment.

    Peptide
    Pegvisomant
    Outcome
    IncreaseOrosomucoid
    Study

    n = 12

    Comparator
    Before pegvisomant treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 mg/day first week, 15 mg/day last two weeks · 3 weeksAs given in this study (human).

    Measurements

    Orosomucoid median
    21 μM
    before pegvisomant treatment
    Orosomucoid interquartile range
    16.3 to 23.8 μM
    before pegvisomant treatment
    Orosomucoid median
    22 μM
    during pegvisomant treatment
    Orosomucoid interquartile range
    17 to 29.3 μM
    during pegvisomant treatment

    Source sentences

    Summary
    Orosomucoid (21.0 (16.3-23.8) vs 22.0 (17.0-29.3) μM, P=0.036) and CRP (1.00 (0.62-1.77) vs 1.43 (0.71-3.29) mg/l, P=0.074) increased without an increase in pro-inflammatory cytokines.
    2 context sentences
    Summary · context
    Twelve healthy volunteers (mean age 36, range 27-49 years) were treated in random order
    Summary · context
    or a GH receptor antagonist (pegvisomant; first week 10  mg/day and last two weeks 15  mg/day), separated by 8 weeks of washout.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, CRP increased from 1.00 (0.62-1.77) to 1.43 (0.71-3.29) mg/l during pegvisomant treatment (P=0.074).

    In plain wordsIn healthy volunteers, CRP increased during pegvisomant treatment compared with before treatment, with P=0.074.

    Peptide
    Pegvisomant
    Outcome
    IncreaseC-reactive protein
    Study

    n = 12

    Comparator
    Before pegvisomant treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 mg/day first week, 15 mg/day last two weeks · 3 weeksAs given in this study (human).

    Measurements

    CRP median
    1 mg/l
    before pegvisomant treatment
    CRP interquartile range
    0.62 to 1.77 mg/l
    before pegvisomant treatment
    CRP median
    1.43 mg/l
    during pegvisomant treatment
    CRP interquartile range
    0.71 to 3.29 mg/l
    during pegvisomant treatment

    Source sentences

    Summary
    Orosomucoid (21.0 (16.3-23.8) vs 22.0 (17.0-29.3) μM, P=0.036) and CRP (1.00 (0.62-1.77) vs 1.43 (0.71-3.29) mg/l, P=0.074) increased without an increase in pro-inflammatory cytokines.
    2 context sentences
    Summary · context
    Twelve healthy volunteers (mean age 36, range 27-49 years) were treated in random order
    Summary · context
    or a GH receptor antagonist (pegvisomant; first week 10  mg/day and last two weeks 15  mg/day), separated by 8 weeks of washout.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, pro-inflammatory cytokines did not increase during pegvisomant treatment.

    In plain wordsIn healthy volunteers, pro-inflammatory cytokines did not increase during pegvisomant treatment compared with before treatment.

    Peptide
    Pegvisomant
    Outcome
    No significant changePro-inflammatory cytokines
    Study

    n = 12

    Comparator
    Before pegvisomant treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 mg/day first week, 15 mg/day last two weeks · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Orosomucoid (21.0 (16.3-23.8) vs 22.0 (17.0-29.3) μM, P=0.036) and CRP (1.00 (0.62-1.77) vs 1.43 (0.71-3.29) mg/l, P=0.074) increased without an increase in pro-inflammatory cytokines.
    2 context sentences
    Summary · context
    Twelve healthy volunteers (mean age 36, range 27-49 years) were treated in random order
    Summary · context
    or a GH receptor antagonist (pegvisomant; first week 10  mg/day and last two weeks 15  mg/day), separated by 8 weeks of washout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.